RADIOPHARM ORDINARY (RAD) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
KalkineRadiopharm Theranostics (ASX:RAD) Announces Finance and Governance Leadership Changes
Highlights Radiopharm Theranostics will continue its service agreement with Acclime Australia for CFO, financial management, statutory reporting and company secretarial services. Aaron Laurita has been appointed CFO, succeeding Phillip Hains. Amritha Sushil has joined the company as Joint Company Secretary, effective immediately. Nathan Jong will continue serving as Joint Company Secretary alongside Sushil. Radiopharm Theranostics (ASX:RAD) has confirmed the continuation of its service agreem...
Radiopharm Theranostics Draws Attention After Insider Buying
Highlights Radiopharm Theranostics insiders continued accumulating shares despite recent market weakness. The healthcare-focused biotech company remains under close watch amid theranostics sector growth. Investor attention remains centred on insider confidence and clinical development progress. Radiopharm Theranostics continues attracting market attention as insider buying activity and growing interest in precision oncology shape sentiment around the emerging healthcare company. The Australia...
Why Is (ASX:RAD) Drawing Attention After Clinical Update?
Highlights Early clinical data signals encouraging tumour targeting Safety profile remains manageable across initial cohort Trial progresses toward higher dosing phase Radiopharm Theranostics has reported early-stage clinical progress, with initial findings pointing to targeted tumour uptake and a stable safety profile, supporting continued development of its investigational therapy. What Is Driving Momentum for (RAD)? Radiopharm Theranostics (ASX:RAD) has entered a significant phase in...
Radiopharm Theranostics (ASX:RAD) to Present Promising Early Data for HER2 Therapy at AACR 2026
Highlights Radiopharm Theranostics will present early clinical data from its HEAT trial at the American Association for Cancer Research Annual Meeting 2026. Initial results from three patients showed tumour uptake of 177Lu-RAD202 at the lowest 30 mCi dose. No dose-limiting toxicities or treatment discontinuations reported. The trial has been cleared to advance to a higher 130 mCi dose cohort following review by the Data Safety and Monitoring Committee. Radiopharm Theranostics Limited (ASX:RAD...
RAD Initial Findings from Phase 1 177Lu-RAD202 Trial
other announcement
Radiopharm (ASX:RAD) Completes Phase 2b Dosing for Brain Metastases Imaging Trial
Highlights Radiopharm Theranostics has completed final patient dosing in the U.S. Phase 2b trial of 18F-RAD101. The study enrolled 30 patients with recurrent brain metastases from various solid tumors. The trial evaluates diagnostic accuracy against MRI with gadolinium. Interim results show 90% concordance with conventional imaging. Clinical trial readout is expected in June 2026. The company plans to transition to a Phase 3 pivotal trial. Radiopharm Theranostics (ASX:RAD) has reached a key m...
RAD Completes Enrollment in Phase 2b Trial of RAD 101
other announcement
Radiopharm Theranostics (ASX:RAD) Advances RAD202 to Higher Dose Level in Phase 1 HEAT Trial
Highlights The DSMC has recommended advancing RAD202 to a 130mCi dose level in the Phase 1 HEAT trial. Radiopharm progresses from Cohort 2 to Cohort 3 in its HER2-positive solid tumour stud. Radiopharm expects to complete Phase 1 dose escalation by the end of 2026. RAD202 targets HER2, a well-established oncology biomarker in multiple solid tumours. Radiopharm Theranostics (ASX:RAD) has received a recommendation from the Data Safety and Monitoring Committee (DSMC) to proceed to the next dose ...
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
other announcement
Radiopharm (ASX:RAD) Strengthens Clinical Pathway for RAD101 with Siemens Collaboration
Highlights Radiopharm Theranostics has signed a clinical supply agreement with Siemens Healthineers for RAD101 in the U.S. Interim Phase 2b data reported 90% concordance with MRI scans, meeting the primary endpoint. The agreement supports supply for an upcoming global Phase 3 registrational trial. RAD101 demonstrated tumour uptake and improved clarity over equivocal MRI findings. The program holds FDA Fast Track status for diagnosing recurrent brain metastases. Radiopharm Theranostics (ASX:RA...
RAD and Siemens Sign Clinical Supply Agreement for RAD101
other announcement
Change of Director's Interest Notice (IT)
director_dealing announcement
Radiopharm Theranostics (ASX:RAD) Begins First-in-Human Trial of RAD 402 for Advanced Prostate Cancer
Highlights Radiopharm Theranostics has dosed the first patient in its Phase 1 RAD 402 trial for advanced prostate cancer. The therapy targets KLK3 and uses Terbium-161 to enable targeted radiopharmaceutical treatment. The trial will assess safety, tolerability, and early signs of clinical activity through dose escalation. Initial clinical data from the first two dose levels are expected in the second half of 2026. Radiopharm Theranostics (ASX:RAD) has begun clinical evaluation of RAD 402 with...
RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
other announcement
Telix Pharma Gains Traction on Radiopharma Progress
Highlights Clinical updates strengthen pipeline outlook Radiopharma focus drives renewed market attention Financial position supports ongoing expansion Telix Pharmaceuticals is drawing attention as clinical progress and a focused radiopharmaceutical strategy support its long-term positioning in oncology innovation. Telix Advances Radiopharma Strategy Amid Market Focus Telix Pharmaceuticals Ltd (ASX:TLX) has recently attracted market attention as developments within its clinical pipeline...
Radiopharm Theranostics (ASX:RAD) Reports High MRI Concordance in Brain Metastases Imaging Trial
Highlights RAD101 achieved 90% concordance with MRI, meeting the primary endpoint in the Phase 2b trial. PET imaging showed selective uptake in brain metastases, improving detection over MRI alone. Early follow-up data indicates positive trends in sensitivity and specificity for RAD101. The study is on track for final data by June 2026, with FDA Fast Track status supporting development. Radiopharm Theranostics Limited (ASX:RAD) has released new interim findings from its Phase 2b clinical tria...
RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
other announcement
Radiopharm Theranostics (ASX:RAD) to Spotlight Oncology Pipeline at NWR Conference
Highlights Radiopharm Theranostics will participate in the NWR Virtual Healthcare Conference to showcase its oncology-focused innovations. CEO & Managing Director Riccardo Canevari will outline the company’s strategy and oncology pipeline. The company is advancing targeted radiopharmaceuticals for cancers with limited treatment options. Clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX:RAD) (NASDAQ:RADX) has announced its participation in the upcoming NWR Virtual...
RAD to present at NWR Virtual Healthcare Conference
other announcement
Radiopharm Theranostics (ASX:RAD) Advances Clinical Pipeline with Key Trial Progress and Funding Boost
Highlights Radiopharm Theranostics is advancing multiple radiopharmaceutical programs across clinical stages RAD 101 has reported 92% concordance with MRI in a Phase 2b brain metastases study RAD 202 and RAD 204 have progressed dose escalation studies with early tumour uptake observed BetaBart (RV-01) has entered clinical trials with the first patient dosed following FDA clearance The company has strengthened its funding position to support new patient dosing, regulatory milestones, and pipelin...
RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
other announcement
RAD Increases Ownership in Radiopharm Ventures to 87.5%
other announcement
Change of Director's Interest Notice (RC)
director_dealing announcement
Change of Director's Interest Notice (PH)
director_dealing announcement
Change of Director's Interest Notice (IT)
director_dealing announcement
RAD announces establishment of At-The-Market Equity Facility
other announcement
RAD101 interim Phase 2b data - 92% achieve primary endpoint
other announcement
New Class Options Range of Units and Top 20 Holders
other announcement
Life Sciences Leader Bruce Goodwin Appointed to Board
other announcement
RAD Approval for Phase 1 Therapeutic Trial of RAD 402
other announcement
RAD Announces 50% Enrollment in Phase 2b Trial of RAD101
other announcement
RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204
other announcement
Notice of Extraordinary General Meeting and Proxy Form
other announcement
Presenting at Deutsche Bank ADR Virtual Investor Conference
other announcement
Change of Director's Interest Notice (RC)
director_dealing announcement